MDGL Q2 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$50M

Net Income

-$49M

EPS (Diluted)

$-3.18

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$388M

Total Liabilities

$45M

Stockholders' Equity

$343M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$28,000	+100.0%
Operating Income	-$50M	-$23M	-121.7%
Net Income	-$49M	-$20M	-148.9%